Pillar Biosciences develops next‑generation sequencing (NGS) testing solutions for precision oncology under its Decision Medicine™ approach. Its proprietary SLIMamp® and PiVAT® technologies power rapid targeted sequencing panels and distributable clinical testing kits. The company offers more than 20 NGS testing kits in IVD or RUO formats and has multiple panels in development. Pillar says it has seen strong commercial growth and is focused on expanding adoption of its kits and biopharma partnerships. Proceeds from the recent financing will be used to grow headcount and infrastructure to support commercial activities and partnerships. The company has operations in Natick, Massachusetts, and says the new capital will help it move closer to profitability. Pillar Biosciences develops NGS-based clinical cancer diagnostics using its SLIMamp®- and PiVAT®-based products to serve high-throughput reference and clinical oncology laboratories. Its panels are compatible with Illumina®, Ion Torrent™, and MGI™ sequencing platforms. The company recently received New York State Department of Health approval for a custom product and CE approval for its first in vitro diagnostic panel, the Pillar® ONCO/Reveal® Lung and Colon Cancer Assay. That assay guides prescription of six therapies simultaneously, reduces repeat testing, and enables treatment decisions in four days. Pillar has secured distributors in Israel, Hong Kong, Macau, South Korea, and ASEAN countries. The company intends to use new funding to accelerate expansion of its IVD and research-use-only panels and advance global commercial outreach. Pillar Biosciences develops NGS-based clinical oncology tests using a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit. The company has released beta versions of a Lung & Colon Cancer Somatic Mutation Panel and a BRCA1 & BRCA2 Germline Mutation Panel to cancer centers and clinical testing companies in the US and China for validation studies. It intends to use recent funding to continue R&D in tumor tissue genotyping and to integrate back-end information analytics capabilities. Pillar also plans to add liquid biopsy products for cancer therapeutic decision-making and treatment monitoring. The company received an $18M venture capital investment to support these efforts.

Total raised

$82M

Funding rounds

3

Latest round

Equity

Latest activity

May 2025